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The effectiveness of an intermittent regimen of transdermal 
nitroglycerin in chronic stable angina was evaluated in 206 
patients using serial treadmill testing. After a placebo 
stabilization phase, patients were randomized to 4 weeks of 
double-blind treatment with transdermal nitroglycerin, 10 
or 20 cm2 (equivalent to 5 or 10 mg124 h) (Group A); 
transdermal nitroglycerin, 30 or 40 cm’ (equivalent to 15 or 
20 mg/24 h) (Group B), or placebo. Patches were applied at 
8:OO AM and removed at 8:00 PM each day throughout the 
study. Treadmill testing was performed 0, 4, 8 and 12 h 
after patch application at baseline (day 0) and on days 1,15 
and 29. 
After short-term application of the transdermal patches, 
treadmill walking time was greater for patients in both 
Group A and Group B than for the placebo group at all 
time points tested; differences from placebo were statisti- 
cally significant at 12 h for Group A and at 4,8 and 12 h for 
Group B. After 2 and 4 weeks of long-term therapy, 
treadmill walking time was again greater for Group B than 
for the placebo group at all postapplication time points; 
differences from placebo reached statistical significance at 
4 h (2 weeks) and 8 h (2 and 4 weeks). The improvement in 
the treadmill walking time seen over the short-term in 
Group A was largely lost after 4 weeks of long-term 
therapy. Potentially important differences in the patient 
characteristics of the two active treatment groups, partic- 
ularly the greater use of a beta-adrenergic blocker among 
patients in Group A, may have contributed to these ob- 
served differences in treatment effect. 
An unexpected finding was the ability of the placebo 
group to exercise longer than either active treatment group 
just before patch application during long-term therapy; 
nonetheless, absolute responsiveness to transdermal nitro- 
glycerin after patch application remained virtually un- 
changed in both active treatment groups during the 4 week 
treatment period. Intermittent transdermal nitroglycerin 
therapy was well tolerated in the vast majority of patients; 
nine patients experienced an increase in nonexertional 
angina during the patch-off periods but completed the study 
uneventfully. 
(J Am Co11 Cardiol1989;13:786-93) 
The 24 h antianginal efficacy of transdermal nitroglycerin 
patches during long-term continuous administration has 
been the subject of considerable controversy over recent 
years. Several studies (l-3) have suggested that the early 
improvement in 24 h exercise tolerance seen with trans- 
dermal nitroglycerin patches is lost or significantly attenu- 
ated over time whereas other studies (4,5) have confirmed 
that efficacy is maintained. It has been proposed that an 
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attenuation of effect may be overcome by using higher doses 
or by allowing a daily nitrate-free period. Several small 
studies (6-9) evaluating intermittent regimens with a daily 
nitrate-free period have produced encouraging results. This 
article reports the results of the Transderm-Nitro Trial, a 
large-scale, double-blind, randomized, placebo-controlled, 
multicenter study evaluating the efficacy and tolerability of 
an intermittent (12 h on/12 h off) regimen of transdermal 
nitroglycerin patches in patients with chronic stable angina. 
Methods 
Patient selection. Study entry criteria. Male and female 
outpatients between 21 and 75 years of age who had a 
primary diagnosis of angina pectoris were eligible for entry 
into the study. Additional entry criteria included the follow- 
ing: 1) Withdrawal of all prophylactic antianginal medica- 
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tion, with the exception of beta-adrenergic blockers, before 
the first visit. Discontinuation of beta-blocker therapy was 
strongly encouraged, but this treatment was permitted in 
patients in whom it could not be withdrawn provided the 
dose and dosage regimen remained constant. 2) Develop- 
ment of moderate angina 3 to 7 min after the start of an 
exercise stress test performed at the first visit. Moderate 
angina was defined as that degree of pain that would nor- 
mally cause the patient to stop exercising or cease whatever 
activity precipitated the angina1 attack. 3) For patients with 
analyzable ST segments, diagnostic ST segment depression 
on the initial stress test. 4) For patients with nonanalyzable 
ST segments, one or more of the following: angiographic 
evidence of ~50% narrowing of the diameter of a major 
coronary artery. documented myocardial infarction occur- 
ring ~3 months before study entry or an unequivocally 
positive thallium stress test. 5) Demonstration of a ~20% 
increase in time to the development of moderate angina on a 
second stress test after the administration of 0.4 mg subling- 
ual nitroglycerin at the first visit. 
Excluded from the study were patients with angina-like 
symptoms of noncardiac origin; cardiac conditions associ- 
ated with angina-like episodes (e.g., aortic stenosis, idio- 
pathic hypertrophic subaortic stenosis, clinically significant 
mitral valve prolapse); history of coronary revascularization 
or myocardial infarction within the previous 3 months; 
impending myocardial infarction; unstable or vasospastic 
angina; pacemaker dependency if in sinus rhythm: sitting 
systolic blood pressure ~100 mm Hg; uncontrolled hyper- 
tension; uncontrolled or brittle diabetes mellitus, or both: 
clinically significant hepatic disease, renal disease or ane- 
mia; thyrotoxicosis; known intolerance to organic nitrate 
drugs; intermittent claudication or other condition that might 
limit treadmill walking; history of noncompliance to medical 
regimens or potential unreliability; serious clinical or labo- 
ratory abnormalities or history of hypertensive encephalop- 
athy or cerebrovascular accident within the past year. Preg- 
nant women, nursing mothers, women of child-bearing 
potential and patients previously randomized into the dou- 
ble-blind phase of the study were also excluded. 
Putients requiring any qf the following concomitant med- 
ications were also excluded: any vasodilator other than 
sublingual nitroglycerin (e.g., long-acting nitrates, hydral- 
azine. dipyridamole, prazosin, minoxidil, captopril), any 
other antianginal medication (except beta-blockers), mainte- 
nance therapy with aspirin (>325 mgiday) or other nonste- 
roidal anti-inflammatory agent. 
Stabilization criteria. Patients fulfilling study entry crite- 
ria entered a 1 to 4 week single-blind placebo stabilization 
phase. To be eligible for randomization into the double-blind 
portion of the trial, patients were required to fulfill the 
following stabilization criteria on three consecutive stress 
tests during the stabilization phase (the last being the 0 h 
stress test on day 0, the day of baseline measurements): 1) 
development of.moderate angina between 2.5 and 7.5 min 
after the start of testing; and 2) a difference in time to 
moderate angina between consecutive tests of 415%. Pa- 
tients fulfilling these stabilization criteria went on to com- 
plete the remaining baseline exercise tests 4, 8 and 12 h after 
placebo patch application on day 0 and were then random- 
ized to one of four doses of transdermal nitroglycerin or 
placebo. 
Study drug regimen. Throughout the study, patients 
wore four IO cm’ transdermal patches for 12 h each day; all 
patches were identical in appearance. Patches were applied 
at approximately 8 AM and removed at approximately 8 PM 
each day. During the stabilization phase and on day 0, all 
patches contained placebo. At randomization, patients were 
assigned to treatment with placebo or transdermal nitroglyc- 
erin at doses of 10. 20, 30 or 40 cm’; individual doses were 
achieved by using appropriate combinations of active and 
placebo patches. Each active patch (supplied as Transderm- 
Nitro) was rated to release 5 mgi24 h of nitroglycerin so that 
doses of IO, 20, 30 and 40 cm’ are equivalent to 5, IO, 15 and 
20 mgi24 h, respectively. 
Study procedures. All treadmill stress tests were per- 
formed according to the standard Bruce protocol. Patients 
were exercised to moderate angina or exhaustion unless a 
safety problem intervened. During the stabilization phase, 
stress tests were performed between 7 and 10 AM before 
patch application. On day 0 (baseline) and on days 1, 15 and 
29 of double-blind treatment, stress tests were performed at 
approximately 7:45 AM before patch application (0 h) and at 
4. 8 and 12 h after patch application. Patches were removed 
after the 12 h stress test. Double-blind medication was begun 
after the 0 h stress test on day 1. 
At all study visits, supine and standing blood pressure 
and heart rate were measured immediately before patch 
application and at 30 min intervals during the 2 h period 
immediately after application of the transdermal systems. 
On days 0, 1, 15 and 29, supine heart rate and blood pressure 
were also measured every 30 min for 2 h after patch removal; 
patients were hospitalized for overnight observation and any 
episodes of angina were recorded. Patient diaries were used 
during the outpatient periods to record each angina1 attack, 
number of nitroglycerin tablets consumed per attack and 
times of patch application and removal. 
Criteria for increase in rest angina. Early in the study, 
specific criteria for a clinically significant increase in rest 
angina during the patch-off periods were developed. These 
criteria were 1) For patients with a history of rest angina and 
at 21 attack of rest angina with patches off during the 
stabilization phase: the occurrence of rest angina with 
patches off during the double-blind phase at an average 
weekly rate that reflected at least a twofold (100%) increase 
as compared with the stabilization phase. 2) For patients 
with a history of rest angina but no attacks of rest angina 
with patches off during the stabilization phase. The occur- 
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Table 1. Disposition of Patients 
Nonrandomized 
Randomized Acceptable for Analysis 
P Group A Group B P Group A Group B 
Completing study 
Prematurely withdrawn 
Reason for withdrawal 
Did not meet study criteria 
Unacceptable concomitant medication 
Adverse experience 
Intercurrent medical problem 
Unsatisfactory therapeutic response 
Death 
Other 
Total 
- 67 63 68 66 63 66 
39 4 5 8 2 4 5 
21 
3 
- 
5 
0 
0 
IO 
39 
0 
71 
Group A = transdermal nitroglycerin (IO to 20 cm’); Group B = transdermal nitroglycerin (30 to 40 cm*); P = placebo. 
rence of an average r2 attacks of rest angina per week with 
patches off during the double-blind phase. 3) For patients 
with no history of rest angina. The occurrence of r3 attacks 
of rest angina with patches off during the double-blind phase. 
The protocol was approved by the institutional review 
board at each participating center. All patients gave written 
informed consent. 
Efficacy variables and sample size considerations. The 
primary efficacy variable was treadmill walking time, defined 
as time to development of moderate angina. When moderate 
angina did not occur, time to termination of test was substi- 
tuted. Secondary stress test variables included time to onset 
of angina, time to I mm increase in ST segment depression 
and total work performed at development of moderate 
angina. Other secondary variables included number of angi- 
nal attacks per week and number of nitroglycerin tablets 
consumed per week as reported in the patient diaries. 
For the purposes of the ejkacy analyses, a previous 
decision was made to pool data from patients receiving 10 or 
20 cm2 of transdermal nitroglycerin (Group A ) and 30 or 40 
cm2 of transdermal nitroglycerin (Group B). The target 
sample size of 60 patients per treatment group (placebo, 
Group A and Group B) was selected to detect a difference of 
30 s in time to development of moderate angina between one 
active treatment group and placebo assuming u2 = 1.25 min, 
cr = 0.05, power ~0.80. All patients who were eligible for 
randomization (per protocol) and had at least one stress test 
performed after receiving randomized medication were con- 
sidered acceptable for the efficacy analysis. 
Statistical methods. The overall comparability of the 
three treatment groups with respect to demographic and 
medical history characteristics of acceptable patients was 
tested using 1) chi-square tests; 2) one-way analysis of 
variance (F tests); and 3) the exact probability tests. Tests 
for the comparability of treatment groups with respect to 
baseline efficacy variables were performed using the F test. 
All but the exact probability test were performed with use of 
procedures from the SAS computer package. All tests were 
conducted with a two-sided alternative hypothesis and a 
level of significance of 0.05. 
In comparing Groups A and B versus the placebo group 
at each time point, using the corresponding time point on 
day 0 as baseline, between-treatment analyses of all stress 
test efficacy variables were performed with use of an analy- 
sis of covariance model including baseline, treatment, treat- 
ment by baseline, center and center by treatment effects; 
small centers were combined to allow inclusion of the center 
by treatment effect in the model. The analysis used Yates 
weighted square of means “technique,” i.e., Type III in the 
GLM procedure from the SAS computer package. Treat- 
ment comparisons were made by examining the differences 
between adjusted treatment means (LSMEANS in the GLM 
procedure) using the Dunnett procedure for making multiple 
comparisons with a control. Between-treatment analyses of 
the number of angina1 attacks and the number of sublingual 
nitroglycerin tablets consumed were performed using the 
Wilcoxon rank sum test. An overall two-sided significance 
level of 0.05 was used for each variable at each time point. 
Results 
Randomization of patients (Table 1). Of the original 254 
patients enrolled in the study, 215 were randomized. The 
predominant reason for withdrawal before randomization 
was failure to meet study criteria. Nine randomized patients 
were considered unacceptable for the efficacy analysis; 
seven of these were in violation of the protocol at random- 
ization and two had no stress tests performed on double- 
blind medication. Of the 206 patients acceptable for the 
efficacy analysis, 68 were assigned to placebo, 67 to 10 to 20 
cm2 of transdermal nitroglycerin (Group A) and 7 1 to 30 to 40 
cm2 of transdermal nitroglycerin (Group B). Seventeen 
patients were prematurely withdrawn from the double-blind 
phase; 11 of these were included in the efficacy analysis. 
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Table 2. Characteristics of Acceptable Patients at Study Entry 
Placebo 
Group Group A Group B 
(n = 68) (n = 67) (n = 71) 
Male (%) 
White (%) 
Mean age (yr) 
Mean duration of angina before 
study tmo) 
Average number of angina1 
attacks/week in last 3 months 
Mean 
Range 
Previous antianginal therapy (c/o) 
Total previously receiving 
antianginal agents 
Calcmm channel blocker 
Long-acting nitrate 
Beta-adrenergic blocker 
On beta-blocker therapy 
at study entry 
Past medical history (%) 
Previous myocardial 
infarctton 
Congestive heart failure 
Diabetes mellitus 
Hypertension 
Peripheral vascular 
disease 
History of coronary 
artery bypass surgery (%o) 
Analyzable ST segments (%I 
Mean % improvement in treadmill 
walking time after sublingual 
nitroglycerin 
89.7 85.1 95.8 
95.6 94.0 95.8 
61.0 61.3 59.5 
70 67 70 
5.3 4.6 
0 to 50 oto21 
92.1 89.7 
36.8 46.3 
51.5 SO.8 
63.2 74.6 
52.9 70. I 
54.4 46.3 
2.9 0.0 
8.8 11.9 
30.9 37.3 
7.4 6.0 
19.1 26.9 
86.8 88.1 
42.0 42.2 
4.6 
I to 36 
80.3 
50.7 
50.7 
57.8 
47.9 
59.2 
1.4 
12.7 
38.0 
4.2 
22.5 
81.7 
37.9 
Clinical features (Table 2). The three treatment groups 
were comparable at study entry for all but one of the 
demographic and medical history variables tested. More 
patients in Group A were on beta-adrenergic blocker therapy 
at study entry; overall between-treatment differences were 
statistically significant for this variable. 
Long-term response. On day 15 of double-blind treat- 
ment, mean time to development of moderate angina was 
greater for both active treatments than for placebo at 4, 8 
and 12 h after patch application; differences from placebo 
were statistically significant at 4 and 8 h for Group B. On 
day 29, mean time to development of moderate angina 
was again greater for Group B than for placebo at 4, 8 and 
12 h; the difference at 8 h was statistically significant. For 
Group A, mean time to development of moderate angina 
was greater than placebo only at the 8 h time point; this 
difference was not statistically significant (Fig. 2). The 
patterns observed for the secondary treadmill variables 
were generally similar. 
Statistically signijcant between-treatment differences At the 0 h time point (just before patch application) on 
were also observedfor the following eficacy variables at the days 15 and 29, the placebo group was able to exercise 
baseline (day 0) visit: time to development of moderate longer to the development of moderate angina than was 
angina (8 and 12 h after patch application), time to onset of either active treatment group. The difference between mean 
angina (12 h after patch application) and total work per- times for the placebo group and Group A was statistically 
formed at development of moderate angina (12 h after patch significant on both days. The difference between mean times 
application). For each variable, the value for Group A was for the placebo group and Group B was statistically signifi- 
lower than that for the placebo group or Group B. cant only on day 29 (Fig. 3). 
Exercise Tolerance 
Short-term response. After the first application of double- 
blind medication (day l), mean time to development of 
moderate angina was greater for both active treatments 
e 
Day 1 [3 Placebo 
Hours After Patcn Applmt~on 
Figure 1. Time (means, SE) to development of moderate angina after 
first application of double-blind medication. *Comparison with 
placebo is statistically significant. Group A = treatment with IO or 
20 cm2 transdermal nitroglycerin: Group B = treatment with 30 or 40 
cm’ transdermal nitroglycerin. 
(transdermal nitroglycerin) than for placebo at all time points 
tested. Differences from placebo were statistically significant 
at 12 h for Group A (10 to 20 cm’) and at 4, 8 and 12 h for 
Group B (30 to 40 cm*) (Fig. 1). Similar trends were 
observed for the secondary treadmill variables. 
Change from 0 h. The absolute responsiveness to trans- 
dermal nitroglycerin was evaluated in a post hoc fashion by 
examining the change in the 0 h from each day in time to 
development of moderate angina (Fig. 4). At each time point, 
absolute responsiveness to transdermal nitroglycerin was 
similar during short- and long-term therapy; differences from 
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7.0 
3 6.5 
c’ 
z 
.t 6.0 
P 
4 
2 
3 5.5 
% 
0 
.g 5.0 
k 
0 
Day 15 
i 
6.5 
6.0 
4 
Hours After Patch Appkation 
placebo were statistically significant at nearly all time points 
tested. 
Individual dose response. Although a previous decision 
was made to pool the 10 to 20 cm2 doses and the 30 to 40 cm2 
doses for the purposes of the formal statistical analysis, 
individual doses were examined in a post hoc fashion. Mean 
changes (unadjusted) from baseline in time to development 
of moderate angina for each of the individual doses are 
plotted in Fig. 5. The 10 cm2 dose appeared to have little 
effect after 4 weeks of treatment; the 20 and 30 cm2 doses, 
however, behaved quite similarly to each other during both 
short- and long-term treatment, with a relatively persistent 
effect for up to 12 h after patch application. Although the 
response at 4 h was greatest with the 40 cm* dose, a more 
rapid attenuation of effect by the 8th and 12th h was seen 
with this dose at all visits. 
Figure 3. Time (means, SE) to development of moderate angina 
before patch application. Komparison with Group A is statistically 
significant; fcomparison with Group A and Group B is statistically 
significant. 
7.0 - Hour 0 
3 m 
2 
6.5 - 
1 15 
Study Day 
0 Placebo 
??Group A 
0 Group B 
* 
Day 29 0 Placebo 
* ??Group A 
Figure 2. Time (means, SE) to develop- 
ment of moderate angina after patch appli- 
cation during chronic therapy. *Com- 
parison with placebo is statistically 
significant. 
Angina1 frequency/sublingual nitroglycerin consumption. 
During the patch-on periods, there was a reduction in both 
the mean number of angina1 attacks per week and the mean 
number of sublingual nitroglycerin tablets consumed per 
week in both Group A and B relative to those in the placebo 
group (postrandomization changes in angina1 attacks per 
week: Group A, -1.11; Group B, -0.91; placebo, -0.38; 
postrandomization changes in nitroglycerin tablets con- 
sumed: Group A, - 1.05; Group B, - 1.05; placebo, -0.39). 
No statistically significant between-treatment differences 
in the overall number of angina1 attacks or nitroglycerin 
tablets consumed per week were observed, however. 
This finding was probably related to the low frequency 
of these end points in all three treatment groups through- 
out the study (baseline angina1 attacks per week/overall 
change after randomization: Group A, 3.231-1.10; Group 
B, 2.37/-0.38; placebo, 2.581-0.41; baseline nitroglycerin 
tablets consumed per week/overall change postrandomiza- 
tion: Group A, 3.16/- 1.12; Group B, 2.351-0.54; placebo, 
2.131-0.38). 
Safety. More patients in the active treatment groups 
reported one or more medical problems after randomization 
compared with patients in the placebo group; these differ- 
ences were statistically significant. The most commonly 
reported medical problem was headache, with an incidence 
of 61 to 70% in the active treatment groups compared with 
14% in the placebo group. The majority of headaches were of 
mild to moderate severity and remained unchanged through- 
out the double-blind phase. There was a tendency for 
headaches to be of greater severity and longer duration in 
Group B. Dizziness was reported in 11 patients, 7 of whom 
were in Group B. Medical problems reported only in the 
active treatment groups included hypotension (five patients), 
syncope (two patients), reactions at site of patch application 
(nine patients) and rebound hypertension after patch re- 
moval (one patient). 
Eight patients, all receiving active treatment, were with- 
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C- Placebo + +-- GroupA + t- Group5 + 
??Day 1 
+ 1.40 ??Day 15 
+ 1.30 EZI Day 29 
Figure 4. Change from 0 h (means, SE) in time to 
development of moderate angina. NT = not tested 
because of statistically significant treatment-by-center 
interaction. *Comparison with placebo is statistically 
significant. 
- .30 j 1 ‘1 
-.40 
4 8 12 4 a 12 4 a 12 
Hours After Patch Appkation 
drawn because of adverse drug reactions; the majority were 
receiving the highest dose of transdermal nitroglycerin (40 
cm*). Reasons for withdrawal included headache (six pa- 
tients) and hypotension (two patients). One death occurred 
during the randomized phase; a patient with a history of 
emphysema who was receiving 40 cm* of transdermal nitro- 
glycerin experienced an acute myocardial infarction approx- 
imately 5 h after patch removal and subsequently died of a 
respiratory arrest. 
Nine patients fuljilled the defined criteria for a significant 
Figure 5. Mean changes from baseline in time to development of 
moderate angina for individual doses on days 1 and 29. 
Day 29 
??= Placebo 
.= lOcm* 
Hours After Patch Appllcatlon 
increase in rest angina during the nitrate-free periods; all 
were receiving active treatment. There was no apparent 
relation to dose of transdermal nitroglycerin. Each episode 
was self-limited or responded promptly to sublingual nitro- 
glycerin. In no case did the investigator feel that the increase 
in rest angina posed a significant risk to the patient; all 
patients completed the study. 
Discussion 
Efficacy of intermittent transdermal nitroglycerin therapy. 
The principal objective of this large multicenter study was 
to compare the efficacy and tolerability of intermittent 
therapy with transdermal nitroglycerin and placebo in the 
treatment of chronic stable angina. Four doses (10, 20, 30 
and 40 cm*) of transdermal nitroglycerin were evaluated 
using a 12 h on112 h off regimen; in keeping with the 
previously conceived statistical plan, data from the two 
lower doses and the two higher doses were pooled for 
the purposes of the primary efficacy analysis. After short- 
term application of the transdermal nitroglycerin patches, 
treadmill walking time was increased for 12 h with both the 
lower and the higher dose regimens; differences from pla- 
cebo were statistically significant at 12 h with the lower dose 
regimen and at all time points tested with the higher dose 
regimen. After 2 and 4 weeks of long-term therapy, treadmill 
walking time was again increased for 12 h after patch 
application with the higher dose regimen; differences from 
placebo were statistically significant at 4 h (2 weeks) and 
at 8 h (2 and 4 weeks). Increases in treadmill walking time 
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were associated with an improvement in time to onset of 
angina, time to 1 mm ST segment depression and total work 
performed. 
The improvement in treadmill walking time seen over the 
short-term with the lower dose regimen (combined 10 to 20 
cm2) was largely lost after 4 weeks of’ long-term therapy. 
Examination of individual doses suggested that the attenua- 
tion of effect occurred predominantly among patients receiv- 
ing 10 cm2 of transdermal nitroglycerin; with the 20 cm2 
dose, a favorable effect on treadmill walking time was seen 
for up to 12 h after patch application during long-term 
therapy. 
The differences observed between the lower dose regimen 
and the higher regimen, particularly with regard to the 
magnitude and time course of response, must be interpreted 
with caution, however, because of potentially important 
differences in the patient characteristics of the two active 
treatment groups. In particular, the greater use of a beta- 
adrenergic blocker among patients receiving the lower dose 
regimen may have made it more difficult to demonstrate a 
treatment effect in that group. 
0 h Findings. An interesting but unexpected observation 
was the ability of the placebo group to exercise longer to the 
development of moderate angina than either active treatment 
group just before patch application during long-term ther- 
apy. Differences were more marked with the lower dose 
regimen than the higher dose regimen, and after 4 weeks of 
therapy than after 2 weeks of therapy. 
This observation has not been previously described in 
association with intermittent nitrate therapy. It is possible 
that patients receiving active treatment developed a sense of 
well-being when patches were in place and were less moti- 
vated to perform at the 0 h just before patch application. 
Alternatively, the 0 h finding may reflect a withdrawal 
phenomenon, perhaps secondary to counter regulatory 
mechanisms such as activation of the renin-angiotensin or 
sympathetic nervous system. Further investigation is re- 
quired to confirm this finding and determine its clinical 
relevance (if any). However, absolute responsiveness to 
transdermal nitroglycerin, as assessed by change in time to 
the development of moderate angina from 0 h on each day, 
did not attenuate over time in either active treatment group. 
This finding would argue against the development of vascu- 
lar tolerance during long-term intermittent therapy with 
transdermal nitroglycerin. 
Tolerability profile. Intermittent transdermal nitroglyc- 
erin therapy was generally well tolerated during the 4 
week treatment period. Despite the high incidence of 
headaches in the active treatment groups, only six patients 
were prematurely withdrawn from the study because of 
headache. Other side effects were reported infrequently 
and led to premature withdrawal in only two additional 
patients. The overall incidence of side effects was compara- 
ble among patients receiving lo,20 or 30 cm2 of transdermal 
nitroglycerin but was somewhat greater among patients 
receiving 40 cm2. 
Conclusions. The overall results of this study demon- 
strate that intermittent (12 h on/12 h oif) transdermal 
nitroglycerin therapy improves exercise tolerance for 8 
to 12 h after patch application during long-term adminis- 
tration in patients with stable angina. Intermittent trans- 
dermal nitroglycerin therapy was well tolerated in the vast 
majority of patients although headache was commonly 
reported. The findings relative to 0 h exercise tolerance 
require further investigation to determine their clinical rele- 
vance. 
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